<DOC>
	<DOC>NCT02740387</DOC>
	<brief_summary>This is a 1-year, multicenter, Phase 2, open-label safety study in subjects with unilateral Meniere's disease. Subjects will receive 1 intratympanic (IT) injection of 12 mg OTO-104 at 3-month intervals for a total of 4 injections total.</brief_summary>
	<brief_title>Open Label Study of OTO-104 in Subjects With Meniere's Disease</brief_title>
	<detailed_description />
	<mesh_term>Meniere Disease</mesh_term>
	<criteria>Inclusion Criteria includes, but is not limited to: Subject has a diagnosis of definite unilateral Meniere's disease. Subject agrees to maintain their current standard of care treatments for Meniere's disease while onstudy. Exclusion Criteria includes, but is not limited to: Subject has an infection in the ear, sinuses, or upper respiratory system. Subject is pregnant or lactating. Subject has a history of immunodeficiency disease. Subject has active or recent (&lt;1 month prior to screening) middle ear disease, including but not limited to: chronic otitis media, acute otitis media, middle ear effusions, middle ear atelectasis, or cholesteatoma. Subject has experienced an adverse reaction to intratympanic injection of steroids.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>